{"url_path":"/sec/pyxs/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1782223/0001193125-26-222843-index.html","accession_number":"0001193125-26-222843","cik":"0001782223","ticker":"PYXS","issuer_name":"Pyxis Oncology, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1782223/0001193125-26-222843-index.html","primary_entity_key":"0001782223","primary_entity_name":"Pyxis Oncology, Inc."},"word_count":323,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\nExhibit\n\nNumber\n\nDescription\n\nForm\n\nFile No.\n\nExhibit\n\nFiling Date\n\nFiled Herewith\n\n10.1\n\n \n\n[General Release Agreement and Indemnification Agreement of Lara Sullivan](pyxs-ex10_1.htm)\n\n \n\n \n\n \n\n \n\nX\n\n31.1\n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](pyxs-ex31_1.htm)\n\nX\n\n31.2\n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](pyxs-ex31_2.htm)\n\nX\n\n32.1*\n\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](pyxs-ex32_1.htm)\n\nX\n\n32.2*\n\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](pyxs-ex32_2.htm)\n\nX\n\n101.INS\n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.\n\nX\n\n101.SCH\n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Document\n\nX\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\nX\n\n \n\n* The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Quarterly Report on Form 10-Q and are not deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in such filing.\n\n67\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nPyxis Oncology, Inc.\n\nDate: May 14, 2026\n\nBy:\n\n   /s/ Thomas Civik\n\nThomas Civik\n\nInterim Chief Executive Officer\n\n \n\n \n\nBy:\n\n  /s/ Jitendra Wadhane\n\nJitendra Wadhane\n\nPrincipal Financial and Accounting Officer\n\n \n\n68"}